• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care
Prostate Cancer : Episode 2

Episode 2 - Immunotherapy in CRPC

Video

During this segment, David Crawford, MD, discusses immunotherapy’s role in castration-resistant prostate cancer (CRPC), and explains how the US Food and Drug Administration’s approval of sipuleucel-T has led to a paradigm shift in the way that CRPC is treated.

Dr Crawford explains the unique capabilities of immunotherapy for advanced disease when compared to conventional treatment options such as cytotoxic chemotherapy.

Additionally, David Quinn, MD, discusses hormonal therapy agents, the key clinical trials that have tested these treatment options, and explains how the trials have demonstrated improved outcomes in CRPC.


Related Videos
Will Shapiro, vice president of data science, Flatiron Health
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Pat Van Burkleo
dr robert sidbury
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Ben Jones, McKesson/Us Oncology
Will Shapiro, vice president of data science, Flatiron Health
Kathy Oubre, MS, Pontchartrain Cancer Center
Jonathan E. Levitt, Esq, Frier Levitt, LLC
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.